{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:47:47Z","timestamp":1790704067053,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Natural Science Foundation for Young Scholars of China","award":["72004151"],"award-info":[{"award-number":["72004151"]}]},{"name":"the Science and Technology Plan Project of Sichuan Province","award":["2020YFS0035"],"award-info":[{"award-number":["2020YFS0035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Evidence of drug-induced liver injury is abundant in adults but is lacking in children. Our aim was to identify suspected drug signals associated with pediatric liver injury.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Hepatic adverse events (HAEs) among children reported in the Food and Drug Administration Adverse Event Reporting System were analyzed. A descriptive analysis was performed to summarize pediatric HAEs, and a disproportionality analysis was conducted by evaluating reporting odds ratios (RORs) and proportional reporting ratios to detect suspected drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here, 14,143 pediatric cases were reported, specifically 49.6% in males, 45.1% in females, and 5.2% unknown. Most patients (68.8%) were 6\u201318 years old. Hospitalization ranked first among definite outcomes (7,207 cases, 37.2%). In total, 264 disproportionate drug signals were identified. The top 10 drugs by the number of reports were paracetamol (1,365; ROR, 3.6; 95% confidence interval (CI), 3.4\u20133.8), methotrexate (878; ROR, 2.5; 95% CI, 2.3\u20132.7), vincristine (649; ROR, 3.0; 95% CI, 2.8\u20133.3), valproic acid (511; ROR, 3.2; 95% CI, 2.9\u20133.6), cyclophosphamide (490; ROR, 2.4; 95% CI, 2.2\u20132.6), tacrolimus (427; ROR, 2.4; 95% CI, 2.2\u20132.7), prednisone (416; ROR, 2.1; 95% CI, 1.9\u20132.3), prednisolone (401; ROR, 2.3; 95% CI, 2.1\u20132.5), etoposide (378; ROR, 2.3; 95% CI, 2.1\u20132.6), and cytarabine (344; ROR, 2.8; 95% CI, 2.5\u20133.2). After excluding validated hepatotoxic drugs, six were newly detected, specifically acetylcysteine, thiopental, temazepam, nefopam, primaquine, and pyrimethamine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The hepatotoxic risk associated with 264 signals needs to be noted in practice. The causality of hepatotoxicity and mechanism among new signals should be verified with preclinical and clinical studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-023-04097-9","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T10:02:09Z","timestamp":1695895329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Liver injury in children: signal analysis of suspected drugs based on the food and drug administration adverse event reporting system"],"prefix":"10.1186","volume":"23","author":[{"given":"Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaomin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"issue":"1","key":"4097_CR1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat reviews Disease primers. 2019;5(1):58.","journal-title":"Nat reviews Disease primers"},{"issue":"5","key":"4097_CR2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","volume":"116","author":"NP Chalasani","year":"2021","unstructured":"Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG Clinical Guideline: diagnosis and management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol. 2021;116(5):878\u201398.","journal-title":"Am J Gastroenterol"},{"issue":"02","key":"4097_CR3","first-page":"257","volume":"20","author":"Y Yu","year":"2017","unstructured":"Yu Y, Mao Y, Chen C. Guidelines for diagnosis and treatment of drug-induced liver injury. J Practical Hepatol. 2017;20(02):257\u201374.","journal-title":"J Practical Hepatol"},{"issue":"8","key":"4097_CR4","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","volume":"156","author":"T Shen","year":"2019","unstructured":"Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, et al. Incidence and etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology. 2019;156(8):2230\u201341e11.","journal-title":"Gastroenterology"},{"issue":"9","key":"4097_CR5","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/ajg.2012.138","volume":"107","author":"KT Suk","year":"2012","unstructured":"Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012;107(9):1380\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4097_CR6","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.23937","volume":"52","author":"A Reuben","year":"2010","unstructured":"Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology (Baltimore MD). 2010;52(6):2065\u201376.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"6","key":"4097_CR7","first-page":"1166","volume":"34","author":"Y Mao","year":"2018","unstructured":"Mao Y. Strengthening the scientific research and supervision of drug-induced liver injury based on big data. J Clin Hepatol. 2018;34(6):1166\u20138.","journal-title":"J Clin Hepatol"},{"issue":"5","key":"4097_CR8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2125.2010.03754.x","volume":"70","author":"C Ferrajolo","year":"2010","unstructured":"Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, et al. Drug-induced hepatic injury in children: a case\/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol. 2010;70(5):721\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4097_CR9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","volume":"52","author":"RJ Fontana","year":"2010","unstructured":"Fontana RJ, Seeff LB, Andrade RJ, Bj\u00f6rnsson E, Day CP, Serrano J, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (Baltimore MD). 2010;52(2):730\u201342.","journal-title":"Hepatology (Baltimore MD)"},{"key":"4097_CR10","unstructured":"Gan Y, Dong Y, zhang H, Xu Z, Chen D, Wang L et al. Clinical characteristics and outcomes of drug-induced liver injury in children: a study of 184 cases. J Clin Hepatol. 2015(08 vo 31):1244\u20137."},{"key":"4097_CR11","doi-asserted-by":"crossref","unstructured":"Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: the Update. Int J Mol Sci. 2015;17(1).","DOI":"10.3390\/ijms17010014"},{"issue":"1","key":"4097_CR12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11095-016-2033-y","volume":"34","author":"N Thakkar","year":"2017","unstructured":"Thakkar N, Salerno S, Hornik CP, Gonzalez D. Clinical Pharmacology Studies in critically Ill Children. Pharm Res. 2017;34(1):7\u201324.","journal-title":"Pharm Res"},{"issue":"5","key":"4097_CR13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpeds.2005.12.051","volume":"148","author":"RH Squires Jr","year":"2006","unstructured":"Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr. 2006;148(5):652\u20138.","journal-title":"J Pediatr"},{"issue":"17","key":"4097_CR14","first-page":"1933","volume":"29","author":"F Li","year":"2020","unstructured":"Li F, Yu Q. International development and domestic situation of pediatric medication development and clinical trials. Chin J New Drugs. 2020;29(17):1933\u20138.","journal-title":"Chin J New Drugs"},{"key":"4097_CR15","unstructured":"FDA, Questions, and Answers on FDA\u2019s Adverse Event Reporting System (FAERS). 2018. https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers"},{"key":"4097_CR16","doi-asserted-by":"crossref","unstructured":"Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting System Database (FAERS). Cancers. 2020;12(4).","DOI":"10.3390\/cancers12040826"},{"issue":"10","key":"4097_CR17","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.16601","volume":"54","author":"TA Wichelmann","year":"2021","unstructured":"Wichelmann TA, Abdulmujeeb S, Ehrenpreis ED. Bevacizumab and gastrointestinal perforations: a review from the FDA adverse event reporting System (FAERS) database. Aliment Pharmacol Ther. 2021;54(10):1290\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"4097_CR18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/JU.0000000000001785","volume":"206","author":"KW Zhang","year":"2021","unstructured":"Zhang KW, Reimers MA, Calaway AC, Fradley MG, Ponsky L, Garcia JA, et al. Cardiovascular events in men with prostate Cancer receiving hormone therapy: an analysis of the FDA adverse event reporting System (FAERS). J Urol. 2021;206(3):613\u201322.","journal-title":"J Urol"},{"issue":"6","key":"4097_CR19","doi-asserted-by":"crossref","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, et al. OpenVigil FDA - Inspection of U.S. american adverse drug events Pharmacovigilance Data and Novel Clinical Applications. PLoS ONE. 2016;11(6):e0157753.","journal-title":"PLoS ONE"},{"key":"4097_CR20","doi-asserted-by":"crossref","unstructured":"Tian X, Zheng S, Wang J, Yu M, Lin Z, Qin M et al. Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review. Exp Opin Drug Saf. 2022:1\u20136.","DOI":"10.1080\/14740338.2022.2078301"},{"key":"4097_CR21","doi-asserted-by":"crossref","first-page":"111767","DOI":"10.1016\/j.fct.2020.111767","volume":"145","author":"Q Wu","year":"2020","unstructured":"Wu Q, Fan X, Hong H, Gu Y, Liu Z, Fang S, et al. Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association. 2020;145:111767.","journal-title":"Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association"},{"issue":"2","key":"4097_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nbt.2113","volume":"30","author":"R B\u00f6hm","year":"2012","unstructured":"B\u00f6hm R, H\u00f6cker J, Cascorbi I, Herdegen T. OpenVigil\u2013free eyeballs on AERS pharmacovigilance data. Nat Biotechnol. 2012;30(2):137\u20138.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"4097_CR23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/11535340-000000000-00000","volume":"33","author":"A Suzuki","year":"2010","unstructured":"Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33(6):503\u201322.","journal-title":"Drug Saf"},{"issue":"2","key":"4097_CR24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bcp.12611","volume":"80","author":"E Raschi","year":"2015","unstructured":"Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015;80(2):285\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"4097_CR25","unstructured":"ICH. Introductory Guide for Standardised MedDRA Queries (SMQs) 21.1. 2018. https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_21_1_english.pdf"},{"key":"4097_CR26","volume-title":"Association between statin use and daptomycin-related musculoskeletal adverse events: a mixed approach combining a meta-analysis and a disproportionality analysis","author":"M Chuma","year":"2022","unstructured":"Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H, et al. Association between statin use and daptomycin-related musculoskeletal adverse events: a mixed approach combining a meta-analysis and a disproportionality analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America; 2022."},{"issue":"6","key":"4097_CR27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cgh.2007.02.016","volume":"5","author":"RA Hansen","year":"2007","unstructured":"Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol hepatology: official Clin Pract J Am Gastroenterological Association. 2007;5(6):729\u201335.","journal-title":"Clin Gastroenterol hepatology: official Clin Pract J Am Gastroenterological Association"},{"issue":"9","key":"4097_CR28","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.2337\/dc18-0210","volume":"41","author":"M Arai","year":"2018","unstructured":"Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous Pemphigoid and Dipeptidyl Peptidase 4 inhibitors: a disproportionality analysis based on the japanese adverse drug Event Report Database. Diabetes Care. 2018;41(9):e130\u2013e2.","journal-title":"Diabetes Care"},{"issue":"7","key":"4097_CR29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00228-002-0484-z","volume":"58","author":"A Bate","year":"2002","unstructured":"Bate A, Lindquist M, Orre R, Edwards IR, Meyboom RH. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur J Clin Pharmacol. 2002;58(7):483\u201390.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"4097_CR30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","volume":"26","author":"E van Puijenbroek","year":"2003","unstructured":"van Puijenbroek E, Diemont W, van Grootheest K. Application of quantitative signal detection in the dutch spontaneous reporting system for adverse drug reactions. Drug Saf. 2003;26(5):293\u2013301.","journal-title":"Drug Saf"},{"issue":"6","key":"4097_CR31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4097_CR32","unstructured":"FDA. Package Insert-Simulect\u00ae (basiliximab). 2003. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/basnov010203LB.htm"},{"key":"4097_CR33","unstructured":"PMDA. Simulect i.v. injection 10\u00a0mg for pediatric. 2021. http:\/\/zy.yaozh.com\/data\/pdf\/00055862.pdf"},{"issue":"12","key":"4097_CR34","first-page":"745","volume":"26","author":"C Zu","year":"2005","unstructured":"Zu C, Li B, Wei Y, Fan W, Huo Y, Deng Z, et al. Application of simulect in liver transplantation patients. Chin J Organ Transplantation. 2005;26(12):745\u20137.","journal-title":"Chin J Organ Transplantation"},{"key":"4097_CR35","volume-title":"Clinical liver transplantation","author":"J Wu","year":"1998","unstructured":"Wu J, Wu M. Clinical liver transplantation. Shanghai, China: Second Military Medical University Press; 1998."},{"issue":"1","key":"4097_CR36","first-page":"8","volume":"11","author":"M Shemshadi","year":"2020","unstructured":"Shemshadi M, Hoseini R, Zareh R, Otukesh H. Use of Basiliximab with the Standard Immunosuppressive Protocol in Pediatric Renal transplantation: a double-blind Randomized Clinical Trial. Int J Organ Transplantation Med. 2020;11(1):8\u201314.","journal-title":"Int J Organ Transplantation Med"},{"key":"4097_CR37","doi-asserted-by":"crossref","unstructured":"Mocarquer A, Pinto V, Buckel E, Lagos E, Pefaur J, Ramirez K et al. Basiliximab: efficacy and tolerability in adults and children. Transplantation Proceedings. 2003;35(7):2518-9.","DOI":"10.1016\/j.transproceed.2003.09.098"},{"key":"4097_CR38","unstructured":"Center UM, VigiBase. WHO\u2019s global database signalling harm and pointing to safer use 2022 [Available from: https:\/\/who-umc.org\/vigibase\/vigibase-who-s-global-database\/"},{"issue":"10","key":"4097_CR39","first-page":"715","volume":"17","author":"H Zhang","year":"2020","unstructured":"Zhang H, Xu L, Xie Y, Geng T, Su F. 201 cases of drug-induced Liver Injury in Children. Chin J Pharmacovigil. 2020;17(10):715\u20139.","journal-title":"Chin J Pharmacovigil"},{"key":"4097_CR40","volume-title":"A single-center cross-sectional study of drug-induced liver injury in children","author":"X Xie","year":"2020","unstructured":"Xie X. A single-center cross-sectional study of drug-induced liver injury in children. Shanxi, China: Shanxi Medical University; 2020."},{"issue":"3","key":"4097_CR41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11901-018-0413-y","volume":"17","author":"DP Frank","year":"2018","unstructured":"Frank DP, Molleston JP. Drug-Induced Liver Injury in Children. Curr Hepatol Rep. 2018;17(3):283\u201391.","journal-title":"Curr Hepatol Rep"},{"key":"4097_CR42","doi-asserted-by":"crossref","unstructured":"Bell TL, Foster, Jennifer N, Townsend ML. Trimethoprim-Sulfamethoxazole\u2013Induced Hepatotoxicity in a Pediatric patient. Pharmacotherapy. 2010.","DOI":"10.1592\/phco.30.5.539"},{"issue":"2","key":"4097_CR43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0034-1375956","volume":"34","author":"H Devarbhavi","year":"2014","unstructured":"Devarbhavi H, Andrade RJ. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. Semin Liver Dis. 2014;34(2):145\u201361.","journal-title":"Semin Liver Dis"},{"issue":"8","key":"4097_CR44","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00228-016-2064-7","volume":"72","author":"K Nakaharai","year":"2016","unstructured":"Nakaharai K, Sakamoto Y, Yaita K, Yoshimura Y, Igarashi S, Tachikawa N. Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score. Eur J Clin Pharmacol. 2016;72(8):1003\u201311.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"4097_CR45","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/0310057X9902700616","volume":"27","author":"A Crerar-Gilbert","year":"1999","unstructured":"Crerar-Gilbert A, Boots R, Fraenkel D, Macdonald GA. Survival following fulminant hepatic failure from fluconazole induced hepatitis. Anaesth Intensive Care. 1999;27(6):650\u20132.","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"4097_CR46","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4103\/jfmpc.jfmpc_330_17","volume":"7","author":"V Gayam","year":"2018","unstructured":"46, Gayam V, Khalid M, Dahal S, Garlapati P, Gill A. Hyperacute liver injury following intravenous fluconazole: a rare case of dose-independent hepatotoxicity. J Family Med Prim Care. 2018;7(2):451\u20134.","journal-title":"J Family Med Prim Care"},{"issue":"05","key":"4097_CR47","first-page":"882","volume":"21","author":"Y Wen","year":"2018","unstructured":"Wen Y, Guo J, Lv L, Qi X. A case of acute liver failure caused by fluconazole. China Pharmacist. 2018;21(05):882\u20133.","journal-title":"China Pharmacist"},{"issue":"5","key":"4097_CR48","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/516975","volume":"25","author":"JA Bronstein","year":"1997","unstructured":"Bronstein JA, Gros P, Hernandez E, Larroque P, Molini\u00e9 C. Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin Infect diseases: official publication Infect Dis Soc Am. 1997;25(5):1266\u20137.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"key":"4097_CR49","doi-asserted-by":"crossref","unstructured":"Pengcheng W, Komal P, Xiao-bo Z, Xiaochao M. Isoniazid metabolism and hepatotoxicity. Acta Pharmaceutica Sinica B. 2016(05 vo 6):384 \u2013 92.","DOI":"10.1016\/j.apsb.2016.07.014"},{"key":"4097_CR50","unstructured":"CDC. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004\u20132008. MMWR Morbidity and mortality weekly report. 2010;59(8):224\u20139."},{"issue":"4","key":"4097_CR51","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.24527","volume":"54","author":"H Devarbhavi","year":"2011","unstructured":"Devarbhavi H, Karanth D, Prasanna KS, Adarsh CK, Patil M. Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology (Baltimore MD). 2011;54(4):1344\u201350.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"2","key":"4097_CR52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-0034-1375952","volume":"34","author":"PH Hayashi","year":"2014","unstructured":"Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134\u201344.","journal-title":"Semin Liver Dis"},{"issue":"3","key":"4097_CR53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jpids\/pit089","volume":"3","author":"SH Chang","year":"2014","unstructured":"Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in children receiving isoniazid therapy for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3(3):221\u20137.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"6","key":"4097_CR54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/clpt.2010.355","volume":"89","author":"IG Metushi","year":"2011","unstructured":"Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther. 2011;89(6):911\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"04","key":"4097_CR55","first-page":"289","volume":"37","author":"Y Wang","year":"2019","unstructured":"Wang Y, Bao J. Research progress on the pathogenesis of isoniazid induced liver injury. J Pharm Pract. 2019;37(04):289\u201393.","journal-title":"J Pharm Pract"},{"issue":"7","key":"4097_CR56","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","volume":"144","author":"ES Bj\u00f6rnsson","year":"2013","unstructured":"Bj\u00f6rnsson ES, Bergmann OM, Bj\u00f6rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419\u201325. 25.e1-3; quiz e19-20.","journal-title":"Gastroenterology"},{"issue":"4","key":"4097_CR57","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/hep.26001","volume":"57","author":"RH Squires","year":"2013","unstructured":"Squires RH, Dhawan A, Alonso E, Narkewicz MR, Shneider BL, Rodriguez-Baez N, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology (Baltimore MD). 2013;57(4):1542\u20139.","journal-title":"Hepatology (Baltimore MD)"},{"key":"4097_CR58","unstructured":"LiverTox: Clinical and Research Information on Drug-. Induced Liver Injury [Internet]: Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012- [updated January 24, 2017. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548556\/"},{"issue":"10","key":"4097_CR59","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jn\/138.10.1872","volume":"138","author":"JN Baumgardner","year":"2008","unstructured":"Baumgardner JN, Shankar K, Hennings L, Albano E, Badger TM, Ronis MJ. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr. 2008;138(10):1872\u20139.","journal-title":"J Nutr"},{"issue":"3","key":"4097_CR60","first-page":"285","volume":"31","author":"Z Bedir","year":"2022","unstructured":"Bedir Z, Erdem KTO, Ates I, Karakurt TCO, Gursul C, Onk D, et al. Effects of ketamine, thiopental and their combination on the rat liver: a biochemical evaluation. Advances in clinical and experimental medicine: official organ. Wroclaw Med Univ. 2022;31(3):285\u201392.","journal-title":"Wroclaw Med Univ"},{"issue":"6","key":"4097_CR61","first-page":"320","volume":"140","author":"JJ van Everdingen-Bongers","year":"1996","unstructured":"van Everdingen-Bongers JJ, Janssen P, Lammens M, Stricker BH, Bravenboer B. Granulomatous hepatitis attributed to the combination pyrimethamine-chloroquine. Ned Tijdschr Geneeskd. 1996;140(6):320\u20132.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"2","key":"4097_CR62","first-page":"129","volume":"94","author":"Y Okazaki","year":"1997","unstructured":"Okazaki Y, Watanabe N, Uchiyama J, Nakano A, Nishizaki Y, Kagawa T, et al. A case of hypersensitivity type of liver injury induced by pyrimetamine and sulfadoxin (Fansidar). Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. 1997;94(2):129\u201332.","journal-title":"Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology"},{"issue":"3","key":"4097_CR63","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-106-3-393","volume":"106","author":"BJ Zitelli","year":"1987","unstructured":"Zitelli BJ, Alexander J, Taylor S, Miller KD, Howrie DL, Kuritsky JN, et al. Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). Ann Intern Med. 1987;106(3):393\u20135.","journal-title":"Ann Intern Med"},{"issue":"07","key":"4097_CR64","first-page":"904","volume":"17","author":"K Hu","year":"2014","unstructured":"Hu K, Tang J, Feng C, Yang L, Wang X. Toxicity characteristics analysis on overdose of chloroquine phosphate\/primaquine phosphate in children. Practical Pharm Clin Remedies. 2014;17(07):904\u20136.","journal-title":"Practical Pharm Clin Remedies"},{"issue":"06","key":"4097_CR65","first-page":"564","volume":"27","author":"K Hu","year":"2011","unstructured":"Hu K, Tang J, He B, Wang X, Ma D. Analysis of adverse reactions of chloroquine combined with primaquine. Pharm J Chin People\u2019s Liberation Army. 2011;27(06):564\u201380.","journal-title":"Pharm J Chin People\u2019s Liberation Army"},{"key":"4097_CR66","doi-asserted-by":"crossref","unstructured":"Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: the Update. Int J Mol Sci 2015 Dec 24;17(1):14.","DOI":"10.3390\/ijms17010014"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-023-04097-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:28:43Z","timestamp":1700580523000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-023-04097-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4097"],"URL":"https:\/\/doi.org\/10.1186\/s12887-023-04097-9","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"12 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval and consent to participate were not obtained for this study because the FAERS database collects spontaneous reports and is publicly available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"492"}}